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Abstract
Background
Double expression of MYC and BCL2 proteins (DE) and double-hit MYC+BCL2/BCL6 trans-
locations (DH) were established as important biomarkers in patients with diffuse large B-cell
lymphoma (DLBCL) by the 2016 revision of the World Health Organization classification of
lymphoid neoplasms. Whether this applies to the subgroup of young patients with high risk
DLBCL is not known. We previously found that in a uniform retrospective population-based
cohort of patients aged 18–60 years with high-risk DLBCL, the addition of etoposide to R-
CHOP chemotherapy (R-CHOEP) resulted in improved survival mainly in patients with ger-
minal center B-cell like (GCB) immunophenotype. The aim of this study was to investigate
the prognostic and predictive value of DE and DH in this patient cohort.
Methods
Data on all young Danish patients diagnosed with de novo high-risk DLBCL 2004–2008 and
treated with R-CHOP or R-CHOEP were obtained from the Danish Lymphoma database
(n = 159). Tumor samples were available from 103 patients. MYC and BCL2 proteins were
analyzed with quantitative immunohistochemistry (IHC) using different cut off values. MYC-,
BCL2- and BCL6-translocations were examined with fluorescent in situ hybridization
(FISH).
Results
DE with MYC>75% and BCL2>85% was an independent negative prognostic marker of pro-
gression free survival (PFS) in patients treated with R-CHOP but not R-CHOEP (p<0.001),
also after exclusion of patients with DH. A predictive effect of DE for response (PFS) to R-
CHOEP vs. R-CHOP was almost significant (p = 0.07). DH was not prognostic in this patient
cohort.
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Conclusion
In young patients with high-risk DLBCL, treatment with R-CHOEP may overcome the nega-
tive prognostic impact of DE observed in patients treated with R-CHOP.
Introduction
Young patients with high-risk diffuse large B-cell lymphoma (DLBCL) constitute a subgroup
of patients for whom improved prognostication is strongly warranted. The vast majority of
studies investigating prognostic markers in DLBCL included elderly patients with mixed clini-
cal features and treated with R-CHOP or R-CHOP-like chemotherapy regimens. In the revised
WHO classification from 2016 [1] cell of origin (COO) [2], double-hit (DH) MYC+BCL2/
BCL6 translocations [3] and double expression (DE) of MYC and BCL2 protein [4;5] were
pointed out as the currently most established and important biomarkers in DLBCL.
Intensive chemotherapy regimens are often used for younger patients with high-risk
DLBCL in attempts to improve outcome from the standard treatment with cyclophosphamide,
doxorubicin, vincristine, prednisone and rituximab (R-CHOP). One such alteration is the
addition of etoposide to R-CHOP, which is used in R-CHOEP [6–10]and DA-EPOCH-R [11–
14]. Reported overall survival (OS) after treatment with R-CHOEP and DA-EPOCH-R varies
between 76%–85% and 77%–94% respectively.
No randomized trials have been conducted comparing R-CHOP and R-CHOEP. Therefore
we collected a unique, retrospective population based cohort including all young Danish
patients diagnosed with high-risk DLBCL from 2004 through 2008 and treated with R-CHOP
or R-CHOEP, with the purpose of comparing outcome and responses to treatment in a “real
world” setting. In addition we wanted to investigate the prognostic and predictive effects of
established biomarkers; cell of origin (COO), double-hit (DH) MYC+BCL2/BCL6 transloca-
tions and double expression (DE) of MYC and BCL2 protein.
We previously published that patients in this cohort treated with R-CHOEP had improved
PFS and OS compared to patients treated with R-CHOP [6]. In addition, we found that the
improved outcome associated with R-CHOEP was mainly observed in patients with germinal
center B-cell like (GCB) immunophenotype [15]. In the current study we aimed to investigate
the prognostic value of MYC, BCL2 and BCL6 gene translocations and MYC and BCL2 protein
expression in the same patient cohort. We wanted to investigate whether these markers were
also of prognostic value in young patients with high-risk DLBCL and if so, whether the prog-
nostic effect was seen after treatment with both R-CHOP and R-CHOEP. We also wanted to
evaluate whether any of the markers could predict response to treatment with R-CHOEP com-
pared with R-CHOP.
Materials and methods
Cohort
A population based, previously well described, cohort of 159 young patients with high-risk
(age aaIPI 2–3) DLBCL [6] was investigated. The cohort was extracted from the Danish Lyfo
Registry [6;16] and included all young (18–60 years) Danish patients diagnosed with de novo
high-risk DLBCL between January 2004 and December 2008. Only patients treated with either
R-CHOP14 or R-CHOEP14 were included. Detailed cohort inclusion criteria and treatment
strategies were previously described [6]. The research was approved by the ethics committees
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in Denmark (H-3-2009-142) and was conducted according to the principles expressed in the
Declaration of Helsinki.
Pathology review
Collection of H&E stained sections, immunohistochemistry sections and formalin-fixed paraf-
fin embedded (FFPE) tissue blocks was successful for the majority of patients (Sections:
n = 133; FFPE tissue blocks: n = 111). Central review was carried out according to the WHO
classification [17] as previously described [15]. After a pathology review, 19 patients were
excluded (transformed from indolent malignant lymphoma (n = 4), HIV (n = 1), Burkitt Lym-
phoma (n = 1), insufficient material to confirm diagnosis (n = 5), T-cell/histiocyte-rich B-cell
lymphoma (n = 7) and intravascular lymphoma (n = 1).
Tissue
FFPE tissue blocks were available from 111 patients. In 103 of these there was sufficient tissue
for further analysis. Samples with a suitable amount of tissue (n = 34) were used for tissue
micro arrays (TMAs) (1 mm cores in duplicate). When the material was sparse, whole tissue-
sections were analyzed (n = 69). Two μm sections were cut for supplemental FISH and IHC
analyses.
Fluorescent in situ hybridization (FISH)
A total of 103 out of the 159 patients had tissue available for FISH. FISH for detection of MYC,
BCL2 and BCL6 translocation was successful in 99 of 103 patients and performed as previously
described [18]. The following FISH probes were used according to the manufacturer’s recom-
mendations: MYC split (ZytoVision, Zyto Light, SPEC CMYC Dual Color Break Apart
Probe), BCL2 split (Dako, BCL2 FISH DNA Probe, Split Signal, Code Y5407) and BCL6 split
(Dako, BCL6 FISH DNA Probe, Split Signal, Code Y5408).
Immunohistochemistry (IHC)
IHC for MYC protein expression was carried out centralized at the Department of Pathology,
Herlev Hospital in accordance with guidelines from routine diagnostic work-up. FFPE tissue
sections were pretreated on “PreTreatment Module” (PT-Link, Dako) including deparaffiniza-
tion, rehydration and epitope retrieval according to the manufacturer’s instructions at high
pH (9.0). “Dako Autostainer Link 48” was used for the immunohistochemical analyses. The
EnVisionTM FLEX+ (Dako) visualization kit was used in accordance with the manufacturer’s
instructions. The monoclonal c-Myc antibody from Epitomics was used (clone y69/EP121),
diluted 1:100 in EnVision Flex Antibody Diluent (Dako).
The remaining IHC analyses were carried out both at local departments of pathology
throughout Denmark as part of the routine diagnostics as well as at the Department of Pathol-
ogy at Herlev Hospital as previously described [15].
IHC was successfully carried out for MYC (n = 103), BCL6 (n = 100), BCL2 (n = 103),
CD10 (n = 103) and MUM1 (n = 75).
MYC and BCL2 were scored as continuous variables as the percentage of positive tumor
cells regardless of the staining intensity. CD10, BCL6 and MUM1 were scored as dichotomous
variables, as positive (>30%) and negative (<30%) and tumors were classified as germinal cen-
ter like (GCB) and non-GCB as previously described by Hans et al. [19].
Scoring of MYC protein expression was carried out independently and blinded by PN
and MOP. Kappa statistics showed very good agreement (MYC>75%, kappa value: 0.83;
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MYC>40%, kappa value: 0.82). The remaining IHC sections were scored by a haematopathol-
ogist (PN, HK, AF, SLN) and MOP as previously described [15]. In cases with a discrepancy of
more than 20% in continuous variables, consensus was obtained by microscopy with a multi-
headed microscope. With a discrepancy below 20%, the score from the experienced haemato-
pathologist was used. In cases with a discrepancy in dichotomous variables, consensus was
obtained by microscopy with a multi-headed microscope.
Statistics
Chi-square test/Fisher’s exact test and the Mann-Whitney test/Kruskal Wallis tests were used
when categorical and continuous variables were compared between groups.
The cumulative probability of death (OS) and relapse (PFS) were estimated with the
Kaplan-Meier method and the differences in OS and PFS between groups were analyzed using
the log-rank test.
Cox proportional hazard models were used to investigate statistical interactions and multi-
variable analyses and here the Wald test was used. P values <0.05 were regarded as significant.
Statistical analyses were carried out using the IBM SPSS Statistics 20 (IBM corp. Armonk, NY,
USA) software and R statistical software version 3.2.3 (R Foundation for Statistical Computing,
Vienna, Austria).
The web application “Cutoff Finder” [20] was used to determine the optimal cutoff points
for MYC and BCL2 protein expression. “Option 5” in which Cox propertional hazard models
including dichotomized variables and the outcome variable progression free survival (PFS)
was used to determine the most optimal cutoff value as the point with the most significant split
(log-rank test)in R-CHOP treated patients.
The primary endpoint was PFS. Secondary endpoints included overall survival (OS) and
overall response rate (ORR) as previously described [15;21].
Funding
This work was supported by the Department of Pathology, Herlev Hospital; Dansk Kræft-
forsknings Fond and Roche A/S (unrestricted grant).
Results
Clinical characteristics
A total of 103 patients were investigated in the study, 63 were treated with R-CHOP and 40
with R-CHOEP. There was no difference in baseline clinical characteristics between the groups
except that patients treated with R-CHOEP were slightly younger (Table 1).
Patients treated with R-CHOEP had significantly improved outcome when compared to
patients treated with R-CHOP with regards to PFS (HR 0.44; 95%CI: 0.22–0.87; p = 0.02). This
finding was not statistically significant regarding OS (HR 0.57; 95%CI: 0.26–1.2; p = 0.16).
Gender and aaIPI were prognostic factors in the total cohort and in R-CHOP treated patients
but not in patients treated with R-CHOEP. Age>55 was a negative prognostic factor in
R-CHOEP but not in R-CHOP treated patients (Table 2).
MYC, BCL2 and BCL6 translocation
FISH results are shown in Table 3. DH translocations were detected in 8/97 (8%) patients,
most of whom (7/8, 88%) had GCB phenotype. MYC, BCL2, BCL6 and DH translocation had
no prognostic impact with respect to PFS or OS, neither in the treatment subgroups nor in the
total cohort. DH translocations were too few to carry out meaningful statistical analyses in the
MYC, BCL2 and BCL6 alterations in patients with B-cell lymphoma treated with R-CHOP or R-CHOEP
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subgroups of R-CHOP and R-CHOEP treated patients but unexpectedly, remarkably few
events were seen (Table 3).
MYC and BCl2 protein expression
MYC and BCL2 protein expression had medians with IQRs on 50% (IQR 30%-70%) and 90%
(IQR 50%-100%) respectively. The optimal cutoff values were MYC>75% and BCL2>85%
(“Cutoff Finder”). The previously published lower cutoff levels MYC>40% and BCL2>70%
were also studied for comparison. Distribution of IHC positive and negative patients with dif-
ferent cutoff values is listed in Table 3.
Patients with MYC>75% had significantly shorter PFS compared to patients with
MYC75% when treated with R-CHOP. This was not seen in patients treated with R-CHOEP
(Table 2, Fig 1)
The Kaplan Meier curves in Fig 1 show how both patients with MYC>75% and MYC
75% seemed to benefit from R-CHOEP treatment when compared to R-CHOP. The differ-
ence in PFS between patients treated with R-CHOP and R-CHOEP was significant for patients
with MYC> = 75% (p = 0.002). For patients with MYC<75% the difference was not significant
(p = 0.2). With regards to OS the differences did not reach statistical significance (Table 2, Fig
1). No significant interactions between MYC>75% and treatment regimen were found (data
not shown).
Patients with BCL2>85% had significantly lower PFS and OS compared to patients with
BCL285% when treated with R-CHOP. This prognostic effect was not seen in patients
treated with R-CHOEP (Table 2, Fig 1). The difference in PFS and OS between patients treated
Table 1. Baseline clinical characteristics and treatment response in all patients and in patients treated with R-CHOP and R-CHOEP.
R-CHOP (n = 63) R-CHOEP (n = 40) TOTAL (n = 103) p*
n % n % n %
Sex F 24 38 21 53 45 44 0.2
M 39 62 19 48 58 56
Ann Arbor stage 1 1 2 0 0 1 1 0.6
2 2 3 3 8 5 5
3 26 41 17 43 43 42
4 32 51 20 50 52 50
Performance status 0–1 43 68 27 68 70 68 0.9
2–4 20 32 13 33 33 32
aaIPI 2 49 78 31 78 80 78 1.0
3 14 22 9 23 23 22
LDH Elevated 60 95 39 98 99 96 0.6
not elevated 3 5 1 3 4 4
Age 55 36 57 32 80 68 66 0.02
Age > 55 27 43 8 20 35 34
Response evaluation CR, Cru, PR 47 75 35 88 82 80 0.3
SD, PD 9 14 3 8 12 12
dead before evaluation 5 8 1 3 6 6
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide,
prednisone; F, female; M, male; aaIPI, age-adjusted international prognostic index; CR, complete remission; CRu, CR unconfirmed; PR, partial remission;
SD, stable disease; PD, progressive disease; LDH, lactate dehydrogenase.
* p -Value: comparing R-CHOP to R-CHOEP.
https://doi.org/10.1371/journal.pone.0186983.t001
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with R-CHOP and R-CHOEP was significant for patients with BCL2> = 85% with regards to
PFS (p = 0.007). Regarding OS the difference was not statistically significant (p = 0.09). For
patients with BCL2<85% these differences were not significant (p = 0.7 and p = 1.0 respec-
tively) (Fig 1). No statistically significant interactions were seen between BCL2>85 and treat-
ment regimen (data not shown).
DE with MYC>75% and BCL2>85% was prognostic in R-CHOP treated patients with
respect to PFS but not OS. In R-CHOEP treated patients DE had no significant prognostic
effect with respect to either PFS or OS. The Kaplan Meier curves (Fig 2) show that both
patients with and without DE seemed to benefit more from R-CHOEP when compared to
Table 3. Baseline molecular characteristics in all patients and in patients treated with R-CHOP and
R-CHOEP.
R-CHOP R-CHOEP TOTAL p
n % n % n %
FISH MYC + 6 10 7 18 13 13 0.2
MYC - 55 87 31 78 86 83
MYC unknown 2 3 2 5 4 4
BCL6 + 17 27 10 25 27 26 0.9
BCL6 - 44 70 28 70 72 70
BCL6 unknown 2 3 2 5 4 4
BCL2 + 17 27 12 30 29 28 0.7
BCL2 - 44 70 26 65 70 68
BCL2 unknown 2 3 2 5 4 4
DH MYC + BCL2/BCL6+ 3 5 5 13 8 8 **
IHC BCL6 > 30% 50 79 36 90 86 83 0.15
BCL6 30% 11 17 3 8 14 14
BCL6 unknown 2 3 1 3 3 3
CD10 > 30% 24 38 18 45 42 41 0.5
CD10 30% 39 62 22 55 61 59
MUM1 > 30% 32 51 16 40 48 47 0.2
MUM1 30% 14 22 13 33 27 26
MUM1 unknown 17 27 11 28 28 27
GCB 30 48 24 60 54 52 0.2
Non-GCB 33 52 16 40 49 48
BCL2 > 85% 35 56 22 55 57 55 1.0
BCL2 85% 28 44 18 45 46 45
BCL2 > 70% 42 67 26 65 68 66 0.9
BCL2 70% 21 33 14 35 35 34
MYC > 75% 11 17 10 25 21 20 0.4
MYC 75% 52 83 30 75 82 80
MYC > 40% 32 51 26 65 58 56 0.2
MYC 40% 31 49 14 35 45 44
DE MYC > 75% + BCL2 > 85% 10 16 9 23 19 18 0.4
DE MYC > 40% + BCL2 > 70% 26 41 17 43 43 42 0.9
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab,
cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; FISH, fluorescent in situ hybridization;
IHC, immunohistochemistry; GCB, germinal center B-cell like;
* p -Value: comparing R-CHOP to R-CHOEP;
** too few patients for meaningful statistical analyses.
https://doi.org/10.1371/journal.pone.0186983.t003
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R-CHOP. The difference in PFS between patients treated with R-CHOP and R-CHOEP was
significant for patients with DE (p = 0.001) and the difference regarding OS was not statisti-
cally significant (p = 0.07). For patients without DE the differences were not significant
(p = 0.3 and p = 0.5) (Table 2, Fig 2). In interaction analysis a possible statistical interaction
Fig 1. Kaplan Meier curves of MYC and BCL2 overexpression in R-CHOP and R-CHOEP treated patients. A: PFS, MYC>75% and
MYC< = 75% in R-CHOP and R-CHOEP treated patients. B: OS, MYC>75% and MYC< = 75% in R-CHOP and R-CHOEP treated patients.
C: PFS, BCL2>85% and BCL2< = 85% in R-CHOP and R-CHOEP treated patients. D: OS, BCL2>85% and BCL2< = 85% in R-CHOP and
R-CHOEP treated patients. Abbreviations: PFS, progression free survival, R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; OS, overall survival, P, p-value
reflecting comparison of all 4 arms.
https://doi.org/10.1371/journal.pone.0186983.g001
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was seen between DE (MYC>75% and BCL2>85%) and the treatment regimen for PFS
(p = 0.07) but this was a non-statistically significant finding. No interaction was seen for OS
(p = 0.2) (Table 2).
When the lower, previously published cutoff values of MYC>40% and BCL2>70% were
applied for survival analysis overall the same results were seen with similar trends in the
Fig 2. Kaplan Meier curves of MYC and BCL2 DE in R-CHOP and R-CHOEP treated patients with high and low cutoff values. A:
PFS, DE (MYC>75% and BCL2>85%) and no DE in R-CHOP and R-CHOEP treated patients. B: OS, DE (MYC>75% and BCL2>85%) and
no DE in R-CHOP and R-CHOEP treated patients. C: PFS, DE (MYC>40% and BCL2>70%) and no DE in R-CHOP and R-CHOEP treated
patients. D: OS, DE (MYC>40% and BCL2>70%) and no DE in R-CHOP and R-CHOEP treated patients. Abbreviations: PFS, progression
free survival, DE, double expression; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab,
cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; OS, overall survival; P, p-value reflecting comparison of all 4 arms.
https://doi.org/10.1371/journal.pone.0186983.g002
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Kaplan Meier plots (Fig 2 and S1 Fig). The difference in PFS between patients treated with
R-CHOP and R-CHOEP was significant for patients with BCL2>70% (p = 0.02). Regarding
OS this difference was not statistically significant (p = 0.07). No differences were seen in
patients treated with R-CHOEP. The differences no longer reached significant levels for
MYC>40% and for DE of MYC>40% and BCL2>70% (Table 2). No statistical interactions
were found (data not shown).
The survival analyses in which the prognostic impact from DE on PFS and OS was studied
was repeated after exclusion of patients with DH translocations. The same tendencies were
seen for both high cutoff values (DE of MYC>75% and BCL2>85%: PFS, R-CHOEP, p = 0.5;
R-CHOP, p<0.001; OS, R-CHOEP, p = 0.6; R-CHOP, p = 0.1) and low cutoff values (DE of
MYC>40% and BCL2>70%: PFS, R-CHOEP, p = 0.8; R-CHOP, p = 0.1; OS, R-CHOEP,
p = 0.9; R-CHOP, p = 0.4).
With regard to response evaluation in the total cohort 4/21 (19%) patients with MYC>75%
had no response to treatment (Stable disease (SD), progressive disease (PD), death) compared
with 14/79 (18%) patients with MYC< = 75% (p = 0.9). There was also no difference after
stratification according to treatment regimen (R-CHOP: 4/11 (36%) vs 10/50 (20%), p = 0.3;
R-CHOEP: 0/10 (0%) vs 4/29 (14%), p = 0.6)
In the total cohort 14/57 (25%) patients with BCl2>85% had no response to treatment com-
pared to 4/43 (9%) of patients with BCL2<85% (p = 0.07). After stratification according to
treatment regimen a significant difference was seen in patients treated with R-CHOP (12/35
(34%) vs 2/26 (8%); p = 0.016) but not with R-CHOEP (2/22 (9%) vs 2/17 (12%); p = 1).
In the total cohort 4/19 (21%) patients with DE had no response to treatment compared to
14/81 (17%) patients without DE (p = 0.7). There was also no statistical difference after stratifi-
cation according to treatment regimen (R-CHOP: 4/10 (40%) vs 10/51 (48%), p = 0.2;
R-CHOEP: 0/9 (0%) vs 4/30 (13%) p = 0.6).
When the lower cutoff values of MYC>40% and BCL2>70% were applied no differences
were seen between groups regarding response to treatment.
Cell of origin
In this study COO was not a significant prognostic factor for PFS or OS in the total cohort, in
R-CHOP or R-CHOEP treated patients (Table 2). The same tendency that GCB patients had
greater benefit from R-CHOEP as previously described [15] was, however, seen in the Kaplan-
Meier curves (S2 Fig).
COO results were previously published as a part of a larger population based study cohort
in which it was shown that GCB patients had greater benefit from R-CHOEP compared to
R-CHOP, with a statistically significant interaction detected between COO and treatment regi-
men [15].
Cell of origin and DE
DE (MYC>75% and BCL2>85%) was more frequently found in patients with GCB phenotype
(14/54, 26%) compared to patients with non-GCB phenotype (5/49, 10%) (p = 0.04). No inter-
actions were found between COO and DE (MYC>75% and BCL2>85%). The prognostic
effect of DE (MYC>75%and BCL2>85%) was studied in both patients with GCB and non-
GCB phenotype treated with R-CHOP and R-CHOEP, respectively. Due to the small number
of patients in these sub-groups the results should be considered with care. Similar findings
were seen in patients with the GCB phenotype. Patients with non-GCB phenotype were too
few in number for meaningful statistical analyses (Table 2).
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Multivariable analysis
A multivariable analysis was carried out in R-CHOP and R-CHOEP treated patients and
included DE (MYC>75% + BCL2>85%) and aaIPI. DE was an independent significant prog-
nostic marker of PFS in R-CHOP treated patients but not in R-CHOEP treated patients
(R-CHOP: DE: HR 4.3; 95%CI: 1.9–9.6; p<0.001; R-CHOEP: DE: HR 0.32; 95%CI: 0.04–2.5;
p = 0.3). With regard to aaIPI, a possible prognostic effect was seen in R-CHOP treated
patients but not in R-CHOEP treated patients (R-CHOP: aaIPI: HR 2.0; 95%CI: 0.93–4.4;
p = 0.08; R-CHOEP: aaIPI: HR 0.86; 95%CI: 0.19–4.0; p = 0.8).
With respect to OS, high aaIPI was a significant negative prognostic marker in patients
treated with R-CHOP (HR 4.0 95%CI: 1.7–9.5; p = 0.002) but not R-CHOEP (HR 1.1 95%CI:
0.23–5.4; p = 0.9). DE had no statistically significant impact on OS in patients treated with
either R-CHOP (HR 2.1; 95%CI: 0.75–5.6; p = 0.16) or R-CHOEP (HR 0.40; 95%CI: 0.05–3.2;
p = 0.4).
Discussion
Only young patients with high-risk DLBCL treated with either R-CHOP or R-CHOEP were
included in this study. The cohort was of limited size, but it was unique and very uniform with
regard to patients’ demographics such as age and treatment, allowing for a unique opportunity
to study, albeit retrospectively, the effects of R-CHOEP compared to a control group of
patients treated with R-CHOP and comparing these responses to established biomarkers such
as COO, DE and DH.
We found that DE of MYC>75% and BCL2>85% had independent negative prognostic
effect in patients treated with R-CHOP but not in patients treated with R-CHOEP. The same
tendencies were seen using previously published cutoffs of MYC>40% and BCl2>70% but
these findings were non-statistically significant. A possible interaction was found between DE
and treatment regimen for PFS but this was also a non-statistically significant finding
(p = 0.07). Based on this DE could be a possible predictive factor for treatment response with
R-CHOEP compared to R-CHOP but this needs further investigation. A possible lack of treat-
ment response was seen in patients with DE in R-CHOP treated patients but this was also a
non-statistically significant finding. The lack of statistical significance in the analyses could
possibly be explained by the limited cohort size. According to the 2016 WHO classification
revision, patients with DH translocations should be excluded from the DLBCL NOS category
and placed within the novel category “High-grade B-cell lymphomas, with MYC and BCL2 or
BCL6 translocations”. We therefore repeated the survival analyses in which the prognostic
impact from DE on PFS and OS was studied after exclusion of patients with DH translocations
and similar findings were seen.
The results suggest that DE in young patients with high-risk DLBCL has prognostic impor-
tance in patients treated with R-CHOP as previously described in cohorts of patients with
DLBCL with mixed clinical features, even though cutoff values in this study were different. By
contrast, DE appeared to have minor prognostic impact in patients treated with R-CHOEP.
The results also suggest that young patients with DE and high-risk DLBCL have improved out-
come after treatment with R-CHOEP when compared to R-CHOP.
Whether DE and DH are prognostic factors in young patients with high-risk DLBCL has
been but poorly investigated. In 2015 Horn et al. published a study of MYC, BCL2 and BCL6
translocations and protein-expression levels in approximately 100 young patients with high-
risk DLBCL enrolled in the R-MegaCHOEP trial [22]. The patients were treated with either
R-CHOEP or R-MegaCHOEP in a prospective randomized setting [9]. The study included no
R-CHOP treated control group. A powerful prognostic effect of BCL2 translocation was
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detected. MYC translocation, MYC protein expression and BCL2 protein expression only
showed trends towards prognostic effects and DH did not indicate increased risk compared to
single hit. The authors concluded that the prognostic value of DE appeared weaker in their
cohort and suggested a potential variable importance of risk factors within clinically different
patient cohorts and treatment groups [22]. The findings by Horn et al. are in accordance with
the findings in the present study in which DE had prognostic value in R-CHOP but not in
R-CHOEP treated young patients with high-risk DLBCL.
In the present study the log rank methodology was used to define the most optimal cutoff
in R-CHOP treated patients using “Cutoff Finder” [20], introduced in order to standardize
detection of cutoff values to reduce the risk of random findings. This methodology, however,
has a risk of overestimating findings and therefore they should be validated in an independent
patient cohort. Unfortunately this was not possible in the current study. However we also
applied previously published cutoff values; MYC>40% and BCL2>70% [4;5] resulting in simi-
lar findings that were, however, not statistically significant. This limitation was possibly at least
in part due to the relatively limited number of patients in the cohort, which implies that only
powerful prognostic factors could be expected to be identified. We found both MYC and
BCL2 protein expression higher than described in most studies. The prevalence of DE was
18% with the high cutoffs and 42% with the lower cutoffs whereas most studies described prev-
alence in between the two. This fact and a limited number of patients in the study makes the
higher cut off values of MYC>75% and BCL2>85% seem reasonable in the current setting
comparing different treatment regimens in small subgroups. Especially because the same ten-
dencies were seen when the lower cut-offs values were applied. It should also be kept in mind
that the patients included in this study all had high-risk DLBCL with a potential association
with MYC and BCL2 levels.
Quantitative IHC for detection of MYC and BCL2 DE has proven difficult to introduce into
clinical practice and different cutoff levels have been proposed by different institutions [23].
Inter-laboratory variation associated with IHC [24] and inter-observer variation especially
regarding MYC scores in cases with heterogeneity or scores close to 40% [25;26] have been
problematic. Standardization remains a precondition for the introduction of biomarkers into
daily clinical practice.
In the current study a DH prevalence of 8% was found and 88% of these had GCB pheno-
type. This is in accordance with findings from previous studies. DH translocations had, how-
ever, no prognostic impact on PFS and OS and surprisingly few events (relapses/deaths) were
observed in patients with these translocations. This could be due to the fact that only young
patients with high-risk disease were included in the cohort but also to the limited number of
patients in the cohort with DH translocation. DH translocations have previously predomi-
nantly been studied in cohorts with older patients [3–5;27–45].
We previously found that patients with GCB immunophenotype benefitted from
R-CHOEP when compared to patients with non-GCB profile. This was not seen in R-CHOP
treated patients and a statistically significant interaction between COO and treatment regimen
was found [15]. In the current study cohort, we found the same tendencies. However, the
results were not statistically significant, possibly because fewer patients were included (S2 Fig).
In contrast with previously published data we found that DE was more frequently found
among patients with GCB profile. This could possibly be explained by the different cutoff val-
ues used. This fact adds a possible bias to our previous findings that COO was predictive of
response to treatment with R-CHOEP [15]. It was not possible to assess whether COO and
DE were independent predictive markers in patients treated with R-CHOP. Further stratifica-
tion of DE in patients with GCB and non-GCB profile respectively resulted in very small
subgroups.
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DA-EPOCH-R was previously suggested for patients with MYC and/or DH translocations
based on preliminary data from a phase II study investigating DA-EPOCH-R in patients with
MYC translocated aggressive lymphomas [11]. It was also suggested that especially patients
with DLBCL and GCB profile or DE might benefit from DA-EPOCH-R [12;13]. Recently, pre-
liminary data from a completed randomized phase III trial was published in which R-CHOP
and DA-EPOCH-R were compared in patients with high-risk DLBCL, and surprisingly similar
outcomes in the two treatment groups were reported [14]. Results from sub-stratification
according to COO, DH translocation and DE in the randomized phase III trial with DA-E-
POCH-R are currently awaited.
In this study we observed that both gender and aaIPI were prognostic in R-CHOP treated
patients as expected, but this was not seen in patients treated with R-CHOEP when a very
favorable outcome was seen (Table 3). Similarly, DE of MYC and BCL2 were not prognostic in
patients treated with R-CHOEP. This underscores how well established prognostic markers in
R-CHOP treated patients might have a more limited prognostic impact in patients treated
with different, more aggressive chemotherapy regimens such as R-CHOEP associated with a
very good outcome. This is of particular importance for future prospective trials with aggres-
sive chemotherapy regimens for which patients are stratified based on these known prognostic
markers. In order to conclude on the predictive value of a given marker, it is very important to
demonstrate a statistically significant interaction between the biomarker investigated and the
treatment regimen investigated [46].
In summary, we found that DE had a negative prognostic impact on outcome in this cohort
of young patients with high-risk DLBCL, treated with R-CHOP but not in patients treated
with R-CHOEP, suggesting that R-CHOEP could possibly overcome the negative prognostic
impact of DE. We also observed a possible predictive value of DE for R-CHOEP compared to
R-CHOP. Patients without DE had no significant benefit from R-CHOEP when compared to
R-CHOP, but non-statistically significant differences were seen in the Kaplan Meier plots and
therefore restriction of R-CHOEP for patients with DE cannot be supported by our data. DH
translocations had no identifiable adverse prognostic impact in the current study, possibly also
due to the limited number of patients. However, we cannot rule out the possibility that it could
be explained by the younger age and/or the high-risk profile of patients. Although the patient
cohort investigated in this study was of limited size the findings deserve further validation.
Supporting information
S1 Fig. Kaplan Meier curves of MYC>40% and BCL2>70% in R-CHOP and R-CHOEP
treated patients. A: PFS, MYC>40% and MYC< = 40% in R-CHOP and R-CHOEP treated
patients. B: OS, MYC>40% and MYC< = 40% in R-CHOP and R-CHOEP treated patients. C:
PFS, BCL2>70% and BCL2< = 70% in R-CHOP and R-CHOEP treated patients. D: OS,
BCL2>70% and BCL2< = 70% in R-CHOP and R-CHOEP treated patients.
Abbreviations: PFS, progression free survival, R-CHOP, rituximab, cyclophosphamide, doxo-
rubicin, vincristine, prednisone; R-CHOEP, rituximab, cyclophosphamide, doxorubicin, vin-
cristine, etoposide, prednisone; OS, overall survival, P, p-value reflecting comparison of all 4
arms.
(TIF)
S2 Fig. Kaplan Meier curves of GCB and Non-GCB phenotype in R-CHOP and R-CHOEP
treated patients. A: PFS, GCB and non-GCB in R-CHOP and R-CHOEP treated patients. B:
OS, GCB and non-GCB in R-CHOP and R-CHOEP treated patients.
Abbreviations: PFS, progression free survival, GCB, germinal center B-cell like; R-CHOP,
rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-CHOEP, rituximab,
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cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; OS, overall survival; P, p-
value reflecting comparison of all 4 arms.
(TIF)
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